Gold bars to be exempt from tariffs, White House clarifies
EL CAJON, Calif. - PURE Bioscience, Inc. (OTCQB: PURE), a micro-cap company with a market value of $10.57 million and annual revenue of $1.86 million, specializing in antimicrobial solutions, has introduced a new application method for membrane treatment in the dairy and beverage industries, employing its patented silver dihydrogen citrate (SDC) technology. According to InvestingPro analysis, the company maintains a healthy gross margin of 58.27% despite its small size. The company announced the launch of its product, PURE Hard Surface, which aims to address the challenges of membrane fouling and sanitization, offering a single-treatment solution that does not compromise the integrity of the membranes.
According to Tom Myers, EVP of Technology & Development at PURE Bioscience, the product’s introduction marks a significant advancement in membrane treatment technology. He highlighted that PURE Hard Surface not only enhances filtration operation and longevity but also delivers efficiency by removing fouling, restoring flow, and delaying the need for membrane replacement.
The company claims that PURE Hard Surface has demonstrated a 4+ log reduction in bacteria in 120 seconds and is NSF-listed, indicating its suitability for the dairy industry. The market has responded positively to PURE’s innovations, with the stock recording a 53.39% gain year-to-date. For detailed financial analysis and more insights, check out InvestingPro, which offers exclusive ProTips and comprehensive metrics for informed investment decisions. The treatment reportedly achieves complete penetration within five minutes for reverse osmosis systems and immediate penetration for ultrafiltration systems, restoring throughput while meeting quality specifications.
The ready-to-use formula is noted for its simplicity, requiring no mixing and no personal protective equipment due to the lowest EPA toxicity rating, making it safe for staff. Furthermore, PURE Bioscience asserts that the environmentally safe treatment poses no risks to wastewater systems and is cost-effective by reducing operational costs and prolonging membrane lifespan.
Tim Steffensmeier, Vice President of Sales, emphasized that the SDC technology represents a smarter, more efficient approach to operations, delivering cost savings and enabling manufacturers to maintain high-quality standards.
SDC operates by deactivating structural and metabolic membrane proteins of microorganisms and denaturing their DNA, which prevents replication and leads to microbial death. Unlike traditional silver-based disinfectants with short shelf lives, SDC is a stabilized silver ion complex with a shelf life of several years. Investors should note that InvestingPro data indicates a weak overall financial health score of 1.67, suggesting careful consideration of the company’s financial position. The stock currently appears overvalued according to InvestingPro’s Fair Value analysis.
The information in this article is based on a press release statement from PURE Bioscience, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.